Trial
NCT06120673
REmission in Membranous Nephropathy International Trial (REMIT)
Phase IIIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
The University of Queensland
Collaborators
University of Adelaide
Condition
Primary Membranous Nephropathy
Intervention
Obinutuzumab
Why stopped
The study was deemed unfeasible due to unforeseen financial limitations
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-11-28